Sarah Diermeier
Dr. Sarah Diermeier is the Founder and Chief Scientific Officer of Amaroq Therapeutics. Amaroq focuses on developing drugs to target long non-coding RNAs, the “dark matter” of the genome, in cancer.
Sarah completed her undergraduate and PhD studies in Biochemistry in Germany. In 2013, she joined Cold Spring Harbor Laboratory in New York to investigate long non-coding RNAs as new therapeutic targets in collaboration with Ionis Pharmaceuticals. In 2018, she was awarded a prestigious Rutherford Discovery Fellowship and moved to New Zealand to start her own research group at Otago University. In 2021, Amaroq was spun out of the University and serves as translational vehicle to bridge the gap between Sarah’s academic research and clinical development of new RNA therapeutics.
Abstracts this author is presenting:
